Company: INCR
Filing Date: 2025-05-01
Form Type: 20-F
Source: 0001641172-25-007971
Chunk: 185

Company: Intercure Ltd.
Filing Date: 2025-05-01
Form: 20-F
Item: Item 18
Chunk 185
---
hereinafter: “XTL”), which constitute 0.44% of XTL’s issued and paid-up capital. 
 
As of the end of the reporting period, the Controlling Shareholder holds 23.63% of XTL shares. 
 
The fair value of these shares as of the end of the reporting period was based on the quoted share price (level 1) as XTL is a publicly traded company listed in the Nasdaq and Tel-Aviv stock exchange, see also Note 12B.

F-30
----
Note 8 – Investment in Subsidiaries:
 
The Company has three main subsidiaries, all in the cannabis sector: Canndoc, Pharmazone, and Cannolam, which are wholly owned (100%).
 

A.                                     Regarding                                  
     the completion of the acquisition of 100% of Cannolam shares, See Note 16(3).
----------------------------------------------------------------------------------

B.       Subsidiaries    
     – Other Acquisitions
-------------------------

Acquisitions
  in 2024   
------------
 
Details in respect of subsidiaries
 

A.                                              On                                          
      January 29, 2024, the Company engaged in an agreement to purchase 100% of “Leon-Pharm”
                                 which operates five pharmacies.                            
--------------------------------------------------------------------------------------------
B.   On                                                                                     
     April 18, 2024, the Company engaged in an agreement to purchase 50% of “New day Eilat” 
     pharmacy, subsequent to which the Company holds 100%. The pharmacy is located in Eilat.
 
Measurement of fair values
 
Presented hereunder is information regarding the techniques the Group used to measure the fair value of the assets and liabilities recognized as a result of the business combination:
 

A.                                          Presented                                        
     below is the fair value, as of the acquisitions dates, of the transferred consideration:
---------------------------------------------------------------------------------------------
 Schedule of Transferred Consideration

                                                                       NIS          
                                                                   in thousands     
------------------------------------------------------------------------------------
Issuance                                                                   8,098    
of 1,590,023 ordinary shares of the Company                                         
Assignment of shareholders’ loan                                          (1,548   )
Fair value of the investment prior to the business combination   202                
Total                                                                      6,752    

B.               Net             
     cash flow in the acquisition
---------------------------------
  Schedule of Acquisition of Cash Flows
 
                                             NIS      
                                         in thousands 
------------------------------------------------------
Consideration paid in cash             -              
Less                                            1,108 
– acquired cash and cash